Your search returned 3 results.

Results
	1.	Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo. [electronic resource] by Guth, B D Seewaldt-Becker, E Himmelsbach, F Weisenberger, H Müller, T H Producer: 19971001 In: Journal of cardiovascular pharmacology vol. 30 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. [electronic resource] by Ferrannini, E Seman, L Seewaldt-Becker, E Hantel, S Pinnetti, S Woerle, H J Producer: 20140311 In: Diabetes, obesity & metabolism vol. 15 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. [electronic resource] by Heise, T Seewaldt-Becker, E Macha, S Hantel, S Pinnetti, S Seman, L Woerle, H J Producer: 20140110 In: Diabetes, obesity & metabolism vol. 15 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search